131 related articles for article (PubMed ID: 29018343)
1. Impact of Gastric
Sun LN; Cao Y; Li YQ; Fang YQ; Zhang HW; Wang MF; Xie LJ; Chen J; Yang ZC; Bian ML; Li H; Zhang PP; Wei JF; Meng L; Zhang XH; Zhao P; Wang YQ
Front Pharmacol; 2017; 8():670. PubMed ID: 29018343
[No Abstract] [Full Text] [Related]
2. Pharmacokinetic/Pharmacodynamic Evaluation of Dexlansoprazole Infusion Injection Compared with Lansoprazole in Healthy Chinese Adults.
Wu L; Liu J; Zheng Y; Zhai Y; Lin M; Wu G; Lv D; Shentu J
Clin Drug Investig; 2019 Oct; 39(10):953-965. PubMed ID: 31338800
[TBL] [Abstract][Full Text] [Related]
3. Effects of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of proton pump inhibitors.
Zhang HJ; Zhang XH; Liu J; Sun LN; Shen YW; Zhou C; Zhang HW; Xie LJ; Chen J; Liu Y; Wang YQ
Pharmacol Res; 2020 Feb; 152():104606. PubMed ID: 31846760
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability, pharmacokinetics and pharmacodynamics of dexlansoprazole injection in healthy Chinese subjects.
Li YQ; Yan ZY; Zhang HW; Sun LN; Jiao HW; Wang MF; Yu LY; Yu L; Yuan ZQ; Meng L; Wang YQ
Eur J Clin Pharmacol; 2017 May; 73(5):547-554. PubMed ID: 28138748
[TBL] [Abstract][Full Text] [Related]
5. The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations.
Echizen H
Clin Pharmacokinet; 2016 Apr; 55(4):409-18. PubMed ID: 26369775
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials.
Vakily M; Zhang W; Wu J; Atkinson SN; Mulford D
Curr Med Res Opin; 2009 Mar; 25(3):627-38. PubMed ID: 19232037
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes.
Horai Y; Kimura M; Furuie H; Matsuguma K; Irie S; Koga Y; Nagahama T; Murakami M; Matsui T; Yao T; Urae A; Ishizaki T
Aliment Pharmacol Ther; 2001 Jun; 15(6):793-803. PubMed ID: 11380317
[TBL] [Abstract][Full Text] [Related]
8. Effects of different omeprazole dosing on gastric pH in non-variceal upper gastrointestinal bleeding: A randomized prospective study.
Chwiesko A; Charkiewicz R; Niklinski J; Luczaj W; Skrzydlewska E; Milewski R; Baniukiewicz A; Wroblewski E; Rosolowski M; Dabrowski A
J Dig Dis; 2016 Sep; 17(9):588-599. PubMed ID: 27518195
[TBL] [Abstract][Full Text] [Related]
9. Safety, pharmacokinetics, and pharmacodynamics of S-(-)-pantoprazole sodium injections after single and multiple intravenous doses in healthy Chinese subjects.
Jiao HW; Sun LN; Li YQ; Yu L; Zhang HW; Wang MF; Yu LY; Yuan ZQ; Xie LJ; Chen J; Meng L; Zhang XH; Wang YQ
Eur J Clin Pharmacol; 2018 Mar; 74(3):257-265. PubMed ID: 29167917
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, pharmacodynamics, and safety of esomeprazole injection/infusion in healthy Chinese volunteers: a five-way crossover study.
Yang H; Li J; Zhao Q; Li J; Shen K; Yang X; Jiang J; Hu P; Qian J
J Gastroenterol Hepatol; 2013 Dec; 28(12):1823-8. PubMed ID: 23800161
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and Pharmacodynamic Modeling Analysis of Intravenous Esomeprazole in Healthy Volunteers.
Liu D; Yang H; Jiang J; Nagy P; Shen K; Qian J; Hu P
J Clin Pharmacol; 2016 Jul; 56(7):816-26. PubMed ID: 26970404
[TBL] [Abstract][Full Text] [Related]
12. CYP2C19 genotype related effect of omeprazole on intragastric pH and antimicrobial stability.
Kita T; Tanigawara Y; Aoyama N; Hohda T; Saijoh Y; Komada F; Sakaeda T; Okumura K; Sakai T; Kasuga M
Pharm Res; 2001 May; 18(5):615-21. PubMed ID: 11465416
[TBL] [Abstract][Full Text] [Related]
13. Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies.
Vakily M; Lee RD; Wu J; Gunawardhana L; Mulford D
Clin Drug Investig; 2009; 29(1):35-50. PubMed ID: 19067473
[TBL] [Abstract][Full Text] [Related]
14. The long-lasting effect of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion in dogs.
Uchiyama K; Wakatsuki D; Kakinoki B; Takeuchi Y; Araki T; Morinaka Y
J Pharm Pharmacol; 1999 Apr; 51(4):457-64. PubMed ID: 10385219
[TBL] [Abstract][Full Text] [Related]
15. Comparator pH study to evaluate the single-dose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release esomeprazole 40 mg.
Kukulka M; Eisenberg C; Nudurupati S
Clin Exp Gastroenterol; 2011; 4():213-20. PubMed ID: 22016582
[TBL] [Abstract][Full Text] [Related]
16. Rapid and ultra-rapid metabolizers with CYP2C19*17 polymorphism do not respond to standard therapy with proton pump inhibitors.
Deshpande N; V S; V V RK; H V V M; M S; Banerjee R; Tandan M; D NR
Meta Gene; 2016 Sep; 9():159-64. PubMed ID: 27419077
[TBL] [Abstract][Full Text] [Related]
17. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH.
Shirai N; Furuta T; Moriyama Y; Okochi H; Kobayashi K; Takashima M; Xiao F; Kosuge K; Nakagawa K; Hanai H; Chiba K; Ohashi K; Ishizaki T
Aliment Pharmacol Ther; 2001 Dec; 15(12):1929-37. PubMed ID: 11736724
[TBL] [Abstract][Full Text] [Related]
18. [Influence of CYP2C19 polymorphism and Helicobacter pylori status on the antisecretory effect of omeprazole in gastroesophageal reflux disease].
Sohn YH; Lee WS; Park CH; Joo YE; Kim HS; Choi SK; Rew JS; Kim SJ
Korean J Gastroenterol; 2006 Sep; 48(3):162-71. PubMed ID: 17047431
[TBL] [Abstract][Full Text] [Related]
19. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.
Saitoh T; Fukushima Y; Otsuka H; Hirakawa J; Mori H; Asano T; Ishikawa T; Katsube T; Ogawa K; Ohkawa S
Aliment Pharmacol Ther; 2002 Oct; 16(10):1811-7. PubMed ID: 12269976
[TBL] [Abstract][Full Text] [Related]
20. An ascending single-dose safety and tolerance study of an oral formulation of rabeprazole (E3810).
Lew EA; Barbuti RC; Kovacs TO; Sytnic B; Humphries TJ; Walsh JH
Aliment Pharmacol Ther; 1998 Jul; 12(7):667-72. PubMed ID: 9701531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]